-
公开(公告)号:US20240294661A1
公开(公告)日:2024-09-05
申请号:US18526959
申请日:2023-12-01
Applicant: Genmab A/S
Inventor: David SATIJN , Sandra VERPLOEGEN , Wim BLEEKER , Steen LISBY , Jan VAN DE WINKEL , Patrick VAN BERKEL , Paul PARREN
CPC classification number: C07K16/30 , A61K45/06 , A61K47/6817 , A61K47/6849 , C07K16/36 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
-
公开(公告)号:US20240091352A1
公开(公告)日:2024-03-21
申请号:US18175894
申请日:2023-02-28
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , A61K47/68 , C07K16/28 , C07K16/30
CPC classification number: A61K39/39558 , A61K47/6801 , A61K47/6855 , A61K47/6857 , A61K47/6869 , C07K16/2863 , C07K16/3061 , A61K2039/505
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
23.
公开(公告)号:US20230365714A1
公开(公告)日:2023-11-16
申请号:US18029472
申请日:2021-10-01
Applicant: GENMAB A/S
Inventor: Louise Koopman , Patrick ENGELBERTS , David SATIJN , Jan Hermen DANNENBERG
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/31 , C07K2317/565 , C07K2317/24 , C07K2317/35 , C07K2317/92
Abstract: The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20230257479A1
公开(公告)日:2023-08-17
申请号:US17642488
申请日:2020-09-11
Applicant: GENMAB A/S
Inventor: David SATIJN , Esther C.W. BREIJ , Bart E.C.G. DE GOEIJ , Kristel KEMPER , Patrick ENGELBERTS , Edward N. VAN DEN BRINK , Rik RADEMAKER , Dennis VERZIJL , Sjeng HORBACH , Paul PARREN , Reshma Abdulla RANGWALA , Sri GHATTA , Ruud BRAKENHOFF , Rieneke VAN DE VEN
CPC classification number: C07K16/30 , A61P1/00 , A61P35/00 , A61K2039/505
Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
-
公开(公告)号:US20230089969A1
公开(公告)日:2023-03-23
申请号:US17817033
申请日:2022-08-03
Applicant: GENMAB A/S , BioNTech SE
Inventor: Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号:US20230087745A1
公开(公告)日:2023-03-23
申请号:US17821837
申请日:2022-08-24
Applicant: GENMAB A/S , BIONTECH SE
Inventor: Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ , Edward VAN DEN BRINK , Dennis VERZIJL
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号:US20230076417A1
公开(公告)日:2023-03-09
申请号:US17714735
申请日:2022-04-06
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Joost MELIS , Tom VINK , Hendrik TEN NAPEL , Esther BREIJ , David SATIJN , Paul PARREN
Abstract: The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain. The first domain specifically binds a target molecule (T), and the second domain specifically binds an internalizing effector protein (E), the second antigen-binding domain having a dissociation constant (KD) with E of between 10−9 and 10−8 M. The multispecific antigen-binding molecule is useful in a method for treating and/or preventing a cancer.
-
公开(公告)号:US20220324980A1
公开(公告)日:2022-10-13
申请号:US17695550
申请日:2022-03-15
Applicant: GENMAB A/S
Inventor: Louise KOOPMAN , Patrick ENGELBERTS , Dennis VERZIJL , Edward N. VAN DEN BRINK , Rik RADEMAKER , Sieto BOSGRA , Frederikke L. EGEROD , David SATIJN , Esther C. W BREIJ
Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20220169738A1
公开(公告)日:2022-06-02
申请号:US17369542
申请日:2021-07-07
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD , Jan VAN DE WINKEL , David SATIJN , Paul PARREN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Edward N. VAN DEN BRINK
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20220033510A1
公开(公告)日:2022-02-03
申请号:US17360438
申请日:2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor: Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
-
-
-
-
-
-
-
-